Back to Home
Free On-DemandOn-Demand Webinar

Breaking the Clot: Factor XIa Inhibition and the Future of Stroke Prevention

Release Date

On-Demand

Expiration Date

On-Demand

Credits

1.0 On-Demand

Topics

Cardiology

Program Description

Despite advancements in acute care, stroke remains a leading cause of long-term disability. In the United States, approximately 800,000 individuals experience a stroke annually, of which nearly 25% are recurrent events. Current guidelines emphasize the TOAST classification to drive therapy selection and emphasize short-term dual antiplatelet therapy to prevent recurrence, though this approach targets the body’s primary clotting pathways and can significantly increase the risk of major hemorrhage. Emerging Factor XIa (FXIa) inhibitors represent a novel approach that targets the amplification phase of the coagulation cascade. This session will review the mechanistic differences between these pathways, equipping pharmacists to better navigate the transition to dual-pathway inhibition. Expert faculty will highlight tools to apply stroke classification systems for precise therapy selection and development of pharmacist-led strategies such as medication therapy management and adherence counseling to support pharmacists as essential antithrombotic stewards in stroke prevention and management.

Target audience: Specialty Pharmacists, Health-System Pharmacists
Type of activity: Application
Release date: June 17, 2026
Expiration date: June 17, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  1. Differentiate non-cardioembolic subtypes using ischemic stroke pathophysiology and Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification to inform selection of evidence-based antithrombotic strategies for secondary prevention
  2. Explain the intrinsic and extrinsic coagulation pathways and how Factor XIa contributes to thrombosis formation
  3. Analyze recent efficacy and safety data pertaining to the use of emerging Factor XIa inhibitors in clinical practice
  4. Identify opportunities for pharmacists to support antithrombotic stewardship through medication therapy management, adherence monitoring, and counseling
                            Breaking the Clot: Factor XIa Inhibition and the Future of Stroke Prevention

                            GET STARTED WITH THIS PROGRAM:

                            Register now to gain access to this program.

                            Create AccountAlready Registered? Login Here

                            This education activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

                            What's Included
                            • Access your activities anytime, anywhere, with a computer, tablet or smartphone
                            • Free access with a PTCE account
                            • Pharmacy education designed to improve patient care

                            Follow Us on Social Media!

                            Course

                            Breaking the Clot: Factor XIa Inhibition and the Future of Stroke Prevention

                            Create Account